Leading the Indian pharmaceutical sector and making a name for itself internationally is Sun Pharma. It offers a wide range of medications in its portfolio and a robust pipeline of new ones in a number of therapeutic fields, including oncology, gastrointestinal, cardiology, and neurology. Sun Pharma has grown its presence in more than 100 nations over the years and has become a top choice for research and development partnerships with top international pharmaceutical businesses.
Future investors and stakeholders are very interested in the share price of Sun Pharma. The demand for high-quality medications and treatments is anticipated to rise as the healthcare sector is predicted to expand dramatically. Sun Pharma has a fantastic chance to use its experience in this situation.
CLICK HERE TO KNOW:
UCO BANK SHARE PRICE TARGET 2023 TO 2030: CAN UCO REACH 100 INR?
Contents
HOW TO BUY SUN PHARMA SHARES?
You have the option to purchase Sun Pharma shares through the following trading platforms:
➤ Zerodha
➤ Upstox
➤ Groww
➤ AngelOne
➤ ICICIDirect
SUN PHARMA IN RECENT NEWS
- Despite experiencing an IT breach, Sun Pharma reassures that its core systems remain unaffected.
- Two brokerages have affirmed their “Buy” recommendations for Sun Pharma shares, highlighting an anticipated upside potential of as much as 18%.
- A Sun Pharma subsidiary has entered into a licensing agreement with a United States-based company to introduce a medication for the treatment of stroke.
- Sun Pharma has obtained approval from Canadian regulatory authorities for its acne control cream.
- LIC has divested more than a 2% stake in Sun Pharma, generating Rs 4,699 crore from the sale.
- Sun Pharma, in collaboration with the US-based company Pharmazz, is set to launch Sovateltide, a groundbreaking drug designed to address acute cerebral ischemic stroke. Notably, this medication can be administered within a 24-hour window following the onset of stroke symptoms, marking a significant advancement in stroke treatment.
SUN PHARMA SHARE PRICE TARGET 2023
| SUN PHARMA SHARE PRICE TARGET 2023 | Maximum Price | Minimum Price |
| September 2023 | ₹1,271.62 | ₹1,132.02 |
| October 2023 | ₹1,481.54 | ₹1,078.11 |
| November 2023 | ₹1,541.70 | ₹1,185.92 |
| December 2023 | ₹1,726.70 | ₹1,328.23 |
The predicted share price for Sun Pharma in 2023 shows a bullish uptrend with a healthy growth percentage. The maximum and minimum share prices range from ₹1,726.70 to ₹1,078.11 throughout the year, indicating potential growth of over 100%.
The stock’s performance is expected to be bolstered by the company’s diversified portfolio, with a strong focus on research and development to create innovative products in various therapeutic areas. Additionally, Sun Pharma’s expansion in more than 100 countries, along with collaborations with leading global pharmaceutical companies, may attract more investors and drive up the share price.
SUN PHARMA SHARE PRICE TARGET 2024
| SUN PHARMA SHARE PRICE TARGET 2024 | Maximum Price | Minimum Price |
| January 2024 | ₹1,817.58 | ₹1,621.85 |
| February 2024 | ₹2,042.22 | ₹1,701.85 |
| March 2024 | ₹2,149.71 | ₹1,747.73 |
| April 2024 | ₹1,954.28 | ₹1,503.29 |
| May 2024 | ₹1,628.57 | ₹1,252.74 |
| June 2024 | ₹1,954.28 | ₹1,503.29 |
| July 2024 | ₹1,661.14 | ₹1,287.71 |
| August 2024 | ₹1,827.25 | ₹1,450.20 |
| September 2024 | ₹1,918.62 | ₹1,475.86 |
| October 2024 | ₹2,257.20 | ₹1,736.30 |
| November 2024 | ₹2,370.06 | ₹1,823.12 |
| December 2024 | ₹2,417.46 | ₹1,859.58 |
The predicted share price target for Sun Pharma in 2024 shows a positive trend with an expected maximum price of ₹2,417.46 and a minimum price of ₹1,252.74. The year is expected to start with a maximum share price of ₹1,817.58 in January 2024 and end with a maximum share price of ₹2,417.46 in December 2024.
Although there may be fluctuations in the share price throughout the year, the overall trend suggests a positive outlook, with expected growth in revenue and profitability.
CLICK HERE:
ICICI BANK SHARE PRICE TARGET 2023 TO 2030: CAN ICICI REACH 3000 INR?
SUN PHARMA SHARE PRICE TARGET 2025
| SUN PHARMA SHARE PRICE TARGET 2025 | Maximum Price | Minimum Price |
| January 2025 | ₹2,465.81 | ₹1,896.77 |
| February 2025 | ₹2,595.58 | ₹1,996.60 |
| March 2025 | ₹2,725.36 | ₹2,096.43 |
| April 2025 | ₹2,433.36 | ₹1,871.82 |
| May 2025 | ₹2,212.15 | ₹1,701.65 |
| June 2025 | ₹2,433.36 | ₹1,871.82 |
| July 2025 | ₹2,317.49 | ₹1,782.68 |
| August 2025 | ₹2,414.05 | ₹1,856.96 |
| September 2025 | ₹2,534.75 | ₹1,949.81 |
| October 2025 | ₹2,686.84 | ₹2,066.80 |
| November 2025 | ₹2,874.91 | ₹2,211.47 |
| December 2025 | ₹2,932.41 | ₹2,255.70 |
The maximum price target for January 2025 is ₹2,465.81, while the minimum price is ₹1,896.77. The maximum price target is expected to increase steadily, reaching ₹2,932.41 in December 2025, while the minimum price target is also expected to rise, reaching ₹2,255.70. This indicates that the share price is likely to remain bullish in the year 2025. However, it’s important to keep in mind that share prices can be affected by various factors, including market conditions, company performance, and global events, which could impact the growth percentage of Sun Pharma’s stock.
SUN PHARMA SHARE PRICE TARGET 2026 TO 2030
| SUN PHARMA SHARE PRICE TARGET BY | Maximum Price | Minimum Price |
| 2026 | ₹2,052.69 | ₹1,436.88 |
| 2027 | ₹1,744.79 | ₹1,221.35 |
| 2028 | ₹3,140.61 | ₹2,198.43 |
| 2029 | ₹6,451.31 | ₹4,515.92 |
| 2030 | ₹7,184.41 | ₹5,029.09 |
For 2026, the maximum price target is predicted to be around ₹2,052.69, while the minimum price target is around ₹1,436.88. This indicates a potential growth rate of approximately 43% to 67% compared to the minimum price target in 2025. Moving further down the line, the maximum and minimum price targets for 2027 are predicted to be around ₹1,744.79 and ₹1,221.35 respectively. The year 2028 shows a significant jump in price targets, with the maximum and minimum predicted to be around ₹3,140.61 and ₹2,198.43. The year 2029 is predicted to show a substantial increase with a maximum price target of ₹6,451.31 and a minimum price target of ₹4,515.92. Finally, for 2030, the maximum price target is predicted to be around ₹7,184.41, while the minimum price target is around ₹5,029.09. These predictions suggest a bullish trend in the coming years, with a potential for substantial growth in Sun Pharma’s share prices.
CLICK HERE TO KNOW:
BANDHAN BANK SHARE PRICE TARGET 2023 TO 2030: CAN BANDHAN BANK REACH 1000 INR?
FINANCIAL STRENGTH OF SUN PHARMA (2019 TO 2023)
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|
| Sales | 29,066 | 32,838 | 33,498 | 38,654 | 43,886 |
| Operating Profit | 6,377 | 6,983 | 8,470 | 10,258 | 11,777 |
| Net Profit | 3,208 | 4,172 | 2,272 | 3,389 | 8,513 |
| EPS | 11.11 | 15.69 | 12.10 | 13.64 | 35.32 |
| Dividend Payout (%) | 25% | 25% | 62% | 73% | 33% |
| Interest Expense | 555 | 303 | 141 | 127 | 172 |
| Depreciation | 1,753 | 2,053 | 2,080 | 2,144 | 2,529 |
| Tax Rate (%) | 16% | 16% | 18% | 24% | 9% |
Over the last five years, the financial performance of the company has displayed noteworthy trends. Sales have steadily increased, reaching Rs 43,886 million in the most recent fiscal year, marking substantial growth. Operating profit also showed robust expansion, nearly doubling from Rs 6,377 million in March 2019 to Rs 11,777 million in March 2023. The net profit has seen fluctuations but achieved an impressive Rs 8,513 million in the latest fiscal year. Earnings per share (EPS) exhibited substantial growth, soaring to Rs 35.32 in March 2023. Despite a varying dividend payout percentage, the company maintained healthy dividends to shareholders. Interest expenses remained relatively stable, while depreciation increased gradually. The company’s tax rate notably decreased over this period, enhancing profitability. These financial indicators collectively portray a positive trajectory, marked by consistent growth in sales and profitability, making it an encouraging outlook for the company’s future prospects.
CLICK HERE FOR MORE:
Emergency Credit Line Guarantee Scheme
POINTS TO NOTE WHILE INVEWSTING IN SUN PHARMA SHARES:
- Over the last 5 years, the company has achieved an impressive profit growth, boasting a Compound Annual Growth Rate (CAGR) of 26.4%.
- Maintaining a consistent pattern, the company has been distributing a healthy dividend payout of 56.0%.
- On the sales front, the company’s performance has been lackluster, with a modest growth rate of 10.6% over the past five years.
- The company’s tax rate appears to be on the lower side.
- Over the last 3 years, the company has recorded a relatively low return on equity, standing at 14.0%.
SUN PHARMA SHARE PRICE TARGET BY EXPERTS:
- Sharekhan advises purchasing shares of Sun Pharmaceutical Industries and has set a target price of Rs 1123.(May 31,2023)
- KR Choksey recommends buying shares of Sun Pharmaceutical Industries, targeting a price of Rs 1172.(June 24,2023)
- Motilal Oswal suggests buying Sun Pharma shares with a target price of Rs 1160.(May 27,2023)
- ICICI Direct advises buying shares of Sun Pharmaceutical Industries, setting a target price of Rs 988.7.(June1,2023)
- JM Financial issues a buy recommendation for Sun Pharmaceutical Industries with a predicted value of Rs 1180.(November 2,2023)
FAQ’s
The maximum share price target of Sun Pharma in 2025 is Rs.₹2,932.41
The maximum share price target of Sun Pharma in 2028 is Rs. 3140.61
The maximum share price target of Sun Pharma in 2029 is Rs. 6451.31
The maximum share price target of Sun Pharma in 2030 is Rs. 7184.51
CONCLUSION: SUN PHARMA
According to Sun Pharma’s financial filings for the previous five years, both its sales and profitability have consistently increased. Positive signs of the company’s financial health include the 15.27% revenue growth rate in FY2022, as well as the 12.70% PAT growth rate during the same fiscal year. Nevertheless, the operational profit margin increased steadily over time, reaching 23.73% in FY2022. A long-term investment in Sun Pharma shares may prove profitable due to the company’s financial stability and growth prospects.
In light of the financial data and expert opinions presented, Sun Pharmaceutical Industries has demonstrated a strong performance with notable profit growth over the years. Multiple brokerage firms, including KR Choksey and Motilal Oswal, have recommended buying shares in the company, underscoring its positive outlook. Sharekhan, JM Financial, and ICICI Direct also provide encouraging targets. These indicators collectively suggest a favorable investment prospect in Sun Pharma’s shares. But before making a choice, it is crucial to carry out more investigation and study, just like with any investment.
Suhani Bhat, a student of Hansraj college, is a finance writer who takes deep interest in stock market, mutual funds, and other financial news. She writes for multiple finance blogs, including Financegradeup.com. Other than English, she also speaks Hindi.